Eisenberg Or 4

What Happened
Or Eisenberg, the Chief Financial Officer of NeuroSense Therapeutics Ltd. (NRSN), purchased 250,000 ordinary shares on June 16, 2026, at $0.80 per share for a total cash outlay of $200,000. This was a direct purchase (transaction code P) in a private placement rather than an open-market sale — a purchase is generally a clearer signal of insider accumulation than routine sales.

Key Details

• Transaction date and price: June 16, 2026 — 250,000 shares at $0.80 per share.
• Total value: $200,000.
• Ownership after transaction: Not specified in the Form 4 filing.
• Filing date: Form 4 filed June 17, 2026 (appears timely; no late-filing flag noted).
• Footnote: The shares were acquired pursuant to a Securities Purchase Agreement dated April 28, 2026, in a private placement exempt from registration under Section 4(a)(2) of the Securities Act (restricted shares).
• Transaction code: P = Purchase.

Context
This was a private placement purchase (restricted shares) rather than an open-market trade. Restricted shares from private placements typically carry resale limitations until registration or an applicable exemption allows sale. The transaction reflects an insider purchase but does not, by itself, explain the CFO’s motivation.